elranatamab
Selected indexed studies
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. (Nat Med, 2023) [PMID:37582952]
- Elranatamab: First Approval. (Drugs, 2023) [PMID:37924427]
- Elranatamab. (, 2006) [PMID:39999248]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. (2023) pubmed
- Elranatamab: First Approval. (2023) pubmed
- Elranatamab. (2006) pubmed
- Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. (2024) pubmed
- Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study. (2024) pubmed
- Elranatamab-bcmm. (2023) pubmed
- Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. (2023) pubmed
- Elranatamab: a new promising BispAb in multiple myeloma treatment. (2023) pubmed
- Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3. (2024) pubmed
- Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results. (2025) pubmed